Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211910 | 1.00 | CYP4A11 (0.35) | CYP4A11CYP4F2DHODHNR4A2NPC1 | |
| SCHEMBL35211913 | 1.00 | CYP4A11 (0.35) | CYP4A11CYP4F2DHODHNR4A2NPC1 | |
| SCHEMBL31342430 | 0.94 | CYP4A11 (0.39) | CYP4A11CYP4F2DHODHNR4A2NPC1 | |
| SCHEMBL31342626 | 0.91 | PRKAB2 (0.33) | DHODH | |
| SCHEMBL31342230 | 0.91 | PRKAB2 (0.33) | DHODH | |
| SCHEMBL35211555 | 0.91 | PRKAB2 (0.33) | DHODH | |
| SCHEMBL35212509 | 0.89 | AR (0.34) | — | |
| SCHEMBL35212228 | 0.89 | AR (0.34) | — | |
| SCHEMBL31341963 | 0.84 | DHODH (0.33) | CYP4A11CYP4F2DHODHTTR | |
| SCHEMBL30880033 | 0.82 | NR4A2 (0.41) | NR4A2NPC1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | CYP4A11 168/4885CYP4F2 500/4885DHODH 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.